2.1. Patients with Congenital Hypothyroidism
Early and continuous treatment with LT4 has been shown to promote normal growth [8, 9] and BMD or other indices of bone health [10–12] in children with congenital hypothyroidism, relative to their euthyroid peers (Fig. ), and normal BMD in adults [13]. Maintenance of a healthy weight and calcium intake appears to be an important determinant of bone health in these children, as in other populations [11].
Mean height and z-scores for bone mineral density and bone quality in adolescent/early adult subjects with congenital hypothyroidism treated early and continuously from birth with levothyroxine. aAd-Sos is “amplitude-dependent speed of sound” (more...)
2.2. Adult Patients with Hypothyroidism
2.2.1. Subclinical Hypothyroidism
Administration of LT4 to women with subclinical hypothyroidism increased the rate of bone turnover although whether this effect of LT4 per se, or a reversal of a previous hypothyroid-induced reduction in bone turnover was unclear [14]. A meta-analysis of studies in populations with subclinical hypothyroidism found no clinically significant reduction in bone loss during LT4 treatment in pre-menopausal women (2.7% after 8.5 years of treatment), but there was more significant bone loss in post-menopausal women (9.0% after 9.9 years of treatment) [15]. In contrast, a randomised, controlled trial found no effect of 14 months of LT4 vs. no treatment on BMD in 17 women with subclinical hypothyroidism [16]. Observational data over 3 years showed that the bone-preserving effect of hormone replacement therapy for post-menopausal women was blunted during administration of LT4 for subclinical hypothyroidism [17]. Finally, BMD in adolescent girls treated with LT4 for subclinical hypothyroidism for 2–5 years had similar BMD to a control group [18].
2.2.2. Overt Hypothyroidism
LT4 dosage >150 mg/day, vs. lower doses, was associated with increased risk of fractures in women aged ≥65 years with hypothyroidism and a prior history of osteoporosis (Fig. ) [19]. There was no significant effect in women without prior osteoporosis in this study. Another cross-sectional, observational study in post-menopausal women found reduced BMD associated with a longer duration of LT4 treatment, with no significant relationship between LT4 dosage and BMD in these women [20]. Another observational study in post-menopausal women found no association between LT4 treatment and bone loss, irrespective of the degree of suppression of TSH [21].
Risk of fractures associated with different daily doses of levothyroxine in a large database population stratified by osteoporosis status at baseline. aNo prior diagnosis of osteoporosis and no prescriptions for bisphosphonates; bprior diagnosis of osteoporosis (more...)
Large database studies have also evaluated the effect of LT4 treatment on bone in general populations of patients with hypothyroidism. In one study, patients receiving LT4 therapy were at increased risk of fractures if they had either a high TSH level (>4 mIU/L) or a suppressed TSH level (≤0.03 mIU/L), compared with patients with TSH within the reference range (Fig. ) [22]. Patients with TSH 0.4–4.0 mIU/L were not at increased risk of fractures in this study. Another large database study of 162,369 people with hypothyroidism, of whom 97% received LT4 during follow-up, found increased fracture risk among those with TSH >10 mIU/L, compared with those well controlled to within the euthyroid range (HR 1.15 (95%CI 1.01–1.31, p = 0.03) [23]. These studies demonstrated the importance of optimisation of LT4 treatment, rather than LT4 treatment per se, for maintaining bone health.
Risk of a composite outcome of osteoporotic fractures or death, according to the prevailing level of thyrotropin (TSH), in a population-based database study of individuals receiving treatment with levothyroxine from the UK. aAdjusted for age, gender, (more...)
A case-control study from Denmark, where all 124,655 patients with a fracture served as cases and 373,962 randomly selected age- and gender-matched people without fractures served as controls, found no association between LT4 treatment and risk of fracture [24]. An analysis of 23,183 LT4 users from the UK General Practice Research Database (i.e. managed in the primary care setting) also found no significant association between LT4 use and fracture risk overall although there was an apparent increased risk in males [25]. Other observational data also did not identify a significant effect of LT4 treatment on bone health [26].
The recent SORTED 1 trial found no difference in effects on bone health measured using circulating levels of C-terminal telopeptide (CTx) levels in very elderly patients (≥80 years) with hypothyroidism randomised to control of TSH in the standard reference range (0.4–4.0 mIU/L), or to a higher target range (4.1–8.0 mIU/L) [27]; see chapter, “Levothyroxine in the Older Patient” for a fuller account of this trial. CTx correlates inversely with TSH, including during treatment with LT4, and may provide a useful marker for following effects of LT4 on bone metabolism [28].
2.3. Effects of Thyrotropin-Suppressive Doses of Levothyroxine
Long-term treatment with high doses of LT4 may be administered to suppress the activity of residual thyroid tumour cells after total thyroidectomy for well-differentiated thyroid carcinoma (see chapter, “Levothyroxine and Cancer”). This setting has been likened to a state of “subclinical hyperthyroidism” by some authors [29].
The application of TSH-suppressive doses of LT4 has raised concern over its effects on bone health, given the known association between hyperthyroidism, osteoporosis and increased risk of fractures, as described above. Indeed, many clinical studies have applied various measures of bone mineral density or other markers of skeletal function to post-surgical, athyroid patients receiving TSH-suppressive therapy. Conflicting results of the effects of TSH suppression were reported in pre-menopausal women (adverse effect [30–41], or no clear adverse effect [42–47]), or post-menopausal women (adverse effect [40, 48, 49] or no clear adverse effect [31, 45, 47, 50–53]). Clear adverse safety signals for osteoporosis during TSH suppression did not emerge from several studies in populations that included female populations of mixed pre-/post-menopausal status [54–60], men [31, 45, 61–63] or a mixture of either gender [37, 64–67] (one small study in a mixed population demonstrated increased bone loss with TSH suppression in patients with thyroid cancer [68]). Trabecular bone score may be a more sensitive measure than bone mineral density of the effects of treatment with LT4 on bone structure this parameter has been used in patients who have [31, 32], or have not [69], received thyroidectomy and TSH suppression for thyroid cancer, although changes in this measure did not correlate with changes in BMD in LT4-treated patients in another study [70]. An absence of marked effects on bone health was also observed in studies in which pre-menopausal women [71–74], post-menopausal women [71, 74, 75] or mixed populations [76, 77] received less intensive TSH-suppressive therapy for benign thyroid nodules, or for goitre.
Several studies evaluated fracture risk. One study found that the 10-year fracture risk (assessed using FRAX, an online risk assessment tool) in women (mean age 52 years) did not correlate significantly with LT4 dose, the duration of LT4 therapy or FT4 [42]. Others found no marked increase in the risk of fractures associated with TSH-suppressive therapy [65, 78, 79]. One study found associations between the intensity of TSH suppression and fracture risk: the incidence of vertebral fractures was 45% for patients with TSH <0.5 mIU/L, compared with 24% for TSH 0.5–1.0 mIU/L and 4% for TSH >1.0 mIU/L [80]. Similarly, the risk of osteoporosis was increased in patients receiving a cumulative LT4 dose over time of >395 mg, but not in patients receiving a lower dose, among 9398 patients with new-onset thyroid cancer followed for an average of 6.6 years [81].
Determinants of bone health in patients receiving TSH-suppressive therapy appear to be complex and multifactorial. A family history of osteoporosis and oestrogen deficiency have been identified as risk factors for adverse effects on bone in this population [57, 58, 82]. TSH-suppressive therapy itself was shown not to affect levels of sex hormone-binding globulin [83]. More data on the relationship of TSH-suppressive therapy and bone health are required, relating to older subjects, and men, in particular, however [84].
1,2.
